Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped up prior to trading on Monday . The stock had previously closed at $19.11, but opened at $21.36. Ascentage Pharma Group International shares last traded at $21.0670, with a volume of 5,707 shares traded.

Analysts Set New Price Targets

Several research firms have issued reports on AAPG. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Oppenheimer initiated coverage on shares of Ascentage Pharma Group International in a research note on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price target for the company. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective for the company. Finally, BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research report on Thursday, March 12th. They set a “buy” rating and a $48.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to MarketBeat, Ascentage Pharma Group International has an average rating of “Buy” and a consensus price target of $48.00.

Ascentage Pharma Group International Price Performance

The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. The company has a fifty day moving average of $24.33 and a 200 day moving average of $30.11.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of large investors have recently made changes to their positions in AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the third quarter worth approximately $204,000. Citadel Advisors LLC bought a new stake in Ascentage Pharma Group International during the third quarter valued at approximately $383,000. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International during the second quarter valued at approximately $391,000. Finally, Tema Etfs LLC purchased a new stake in Ascentage Pharma Group International during the second quarter valued at approximately $610,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.